Sharemaestro Newsreel

Altimmune (ALT) CEO Jerome Durso purchases 15,000 shares at $2.95 each

Altimmune, Inc.'s President and CEO, Jerome Benedict Durso, purchased 15,000 shares of the company's common stock at $2.95 per share on August 13, 2026. This transaction, conducted in the open market or a private transaction, increased his direct holdings to 62,500 shares. The Form …

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Elicio Therapeutics announced its second-quarter 2026 financial results and provided corporate updates, including plans to initiate a Phase 1 combination study of ELI-002 7P for metastatic pancreatic cancer in Q4 2026, following observations of multiple complete responses. While its Phase 2 AMPLIFY-7P trial did …

Akari Therapeutics reports Q2 2026 net loss $4.8M, raises ~$8.6M, advancing AKTX-101 toward mid-2027 Phase 1

Akari Therapeutics reported a net loss of $4.8 million for Q2 2026 and held $7.7 million in cash. The company raised approximately $8.6 million in gross proceeds through a private placement and warrant exercises. Akari is advancing its lead ADC candidate, AKTX-101, towards a …

AXSOME THERAPEUTICS, INC. : MIZUHO RAISES TARGET PRICE TO $316 FROM $306

Mizuho has increased its target price for Axsome Therapeutics, Inc. to $316, up from the previous $306. This adjustment indicates a positive outlook from the analyst firm regarding the biopharmaceutical company's future performance.

Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements

Alumis Inc. reported its second-quarter 2026 financial results, highlighting strong long-term data for envudeucitinib in plaque psoriasis, with 54% of patients achieving complete skin clearance. The company plans to submit a New Drug Application for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026 and …

Abeona Therapeutics (NASDAQ:ABEO) Issues Quarterly Earnings Results, Misses Estimates By $0.12 EPS

Outlook Therapeutics (OTLK) Q3 Earnings Preview: Valuation Chall

ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints

Ascendis Pharma A/S Q2 Earnings Call Highlights

Ascendis Pharma A/S reported strong Q2 2026 results, with total revenue more than doubling year-over-year due to increased demand for its TransCon-based therapies. Yorvipath and Yuviwel showed significant growth and early momentum, respectively, contributing to the company's positive financial outlook. Ascendis also outlined pipeline …

Fractyl Health, Inc. - Common Stock (Nasdaq:GUTS) Stock Quote

This article provides a stock quote for Fractyl Health, Inc. (Nasdaq: GUTS), detailing its current price, daily range, volume, and performance metrics. It also includes recent news headlines and press releases related to the company's financial results, clinical trial updates, and investor events. Key …

Mirum Pharmaceuticals (MIRM) Stock Looks Fairly Valued After Recent News

Mirum Pharmaceuticals (MIRM) stock is currently considered fairly valued despite significant share price gains over the past five years. The company's P/S ratio of 10.4x is below the biotech industry average, suggesting it might still be on the inexpensive side. The future performance of …

CYTK Maintained by Barclays -- Price Target Raised to $110

Barclays has maintained an Overweight rating for Cytokinetics (CYTK) and increased its price target to $110, reflecting a positive outlook despite the company being unprofitable. The stock is considered undervalued by 60.9% according to GF Value™, but its GF Score™ of 51/100 indicates average …

Top trending stocks today: ARX, OMER, TMS lead the market movers

Accelerant Holdings (ARX), Omeros Corporation (OMER), and Teamshares Inc. (TMS) were among the top trending stocks, experiencing significant surges due to major news or earnings momentum. Accelerant Holdings saw a 43.2% jump after an announced all-cash buyout, Omeros Corporation rose 24.5% following impressive Q2 …

Alto Neuroscience stock hits all-time high at 32.74 USD

Alto Neuroscience Inc. (ANRO) stock has reached an all-time high of $32.74, marking a 906.09% increase over the past year. Despite this surge, InvestingPro suggests the stock may be overvalued. The company recently announced a stock offering to raise $100 million, received a reiterated …

Anavex Life Sciences Files Proxy, Urges Director Support

Anavex Life Sciences has filed definitive proxy materials for its 2026 Annual Meeting, urging stockholders to support its six director nominees. This move follows a leadership change and a board refresh effort, with the company highlighting progress on its lead CNS candidate, blarcamesine, and …

MediWound Ltd (MDWD) (Q2 2026) Earnings Call Highlights: Record NexoBrid Sales and EscharEx ...

MediWound Ltd (MDWD) reaffirmed its full-year 2026 revenue guidance, citing strong NexoBrid sales and progress in the EscharEx Phase 3 trial. Despite a Q2 revenue decline and increased operating loss, the company anticipates future growth from the expanded EscharEx market assessment and new agreements. …

PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy

PTC Therapeutics has won a bankruptcy auction for Sangamo Therapeutics' gene therapy candidate, isaralgagene civaparvovec (ST-920), for Fabry disease, with a bid of $111 million upfront and up to $100 million in milestone payments. This acquisition expands PTC's rare disease pipeline, bringing a therapy …

(VKTX) Price Dynamics and Execution-Aware Positioning

This article provides an analysis of Viking Therapeutics Inc. (NASDAQ: VKTX) price dynamics, highlighting a neutral near-term sentiment that could moderate mid-term weakness. It identifies a mid-channel oscillation pattern and an exceptional short setup with a 50.5:1 risk-reward ratio. The analysis also details institutional …

Contineum Therapeutics (NASDAQ:CTNM) Trading 6.8% Higher - Should You Buy?

Ovid Therapeutics (NASDAQ:OVID) Announces Earnings Results, Beats Estimates By $0.02 EPS

Ovid Therapeutics (NASDAQ:OVID) announced its quarterly earnings, reporting a loss of $0.08 per share, which beat analysts' estimates by $0.02. The company also surpassed revenue expectations, bringing in $0.73 million against a consensus of $0.02 million. Following the positive results, shares of OVID increased …

IN8BIO, Inc. (INAB) investor discloses 9.99% stake and warrant holdings

Laurence W. Lytton and the Lytton-Kambara Foundation have filed an amended ownership report for IN8BIO, Inc. (INAB), indicating a beneficial ownership of 1,056,513 shares, which includes common stock and warrants, representing 9.99% of the company's outstanding shares. This stake is subject to a 9.99% …

Evogene Ltd. (EVGN) investors lift beneficial stake to 19.35% of shares

Evogene Ltd. shareholders, led by L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd., have increased their beneficial ownership to 19.35% of the company's outstanding shares. This follows Pure Capital's open-market purchase of 533,088 additional American Depositary Shares (ADSs). The reporting persons collectively …

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Equillium, Inc. (Nasdaq: EQ) reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company expects to initiate a Phase 1 proof-of-mechanism study for EQ504 in Q4 2026, with data anticipated approximately six months later. Equillium …

ADC Therapeutics (NYSE:ADCT) Posts Earnings Results, Beats Estimates By $0.11 EPS

ADC Therapeutics (NYSE:ADCT) announced its latest earnings, reporting a loss of $0.11 EPS, which beat the consensus estimate by $0.11. The company's revenue reached $19.25 million, also surpassing expectations. Key takeaways from the earnings call include FDA concerns about the LOTIS-5 combination therapy, progress …

Invesco Ltd. (LGND holder) reports 6.1% beneficial stake in Ligand Pharmaceuticals

Invesco Ltd. has reported a 6.1% beneficial ownership stake in Ligand Pharmaceuticals Inc., according to a recent SCHEDULE 13G SEC filing. This represents 1,218,846 shares of Ligand's common stock, with Invesco exercising sole voting power over 1,199,033 shares and sole dispositive power over all …

Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results

Fate Therapeutics (NASDAQ:FATE) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Fate Therapeutics (NASDAQ:FATE) reported its quarterly earnings, exceeding analyst expectations with an adjusted loss of $0.25 per share, $0.02 better than estimates, and revenue of $2.08 million against a consensus of $1.37 million. Despite beating expectations, the biopharmaceutical company remains unprofitable, showing a negative …

Dogwood Therapeutics (NASDAQ:DWTX) Releases Earnings Results, Misses Estimates By $0.21 EPS

Belite Bio (NASDAQ:BLTE) Posts Quarterly Earnings Results, Beats Estimates By $0.19 EPS

Tarsus (TARS) Q2 2026 Earnings Call Transcript

Monopar Therapeutics Shares Drop After Downgrade From Cantor Fitzgerald

Monopar Therapeutics' shares dropped following a downgrade from Cantor Fitzgerald, which revised its rating from Overweight to Neutral and adjusted the price target from $109 to $119. This news comes amidst other recent developments for the company, including its Q2 earnings report and FDA …

JonesTrading Forecasts Strong Price Appreciation for Septerna (NASDAQ:SEPN) Stock

Ocugen (OCGN) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chairman, Chief Executive Officer, and Co-Founder - Shankar MusunuriChief Financial Officer - Rita Johnson-GreeneExecutive Vice President of Commercial and Business Development - Abhi GuptaChief Medical Officer - Mohamed …

Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Eledon Pharmaceuticals announced its second quarter 2026 financial results and key business highlights, including successful progress in its tegoprubart program. The company is on track to initiate a global Phase 3 kidney transplantation trial in late 2026, supported by positive long-term Phase 2 BESTOW …

DiaMedica Therapeutics Inc. (DMAC) stock price, news, quote and history

This article provides a comprehensive overview of DiaMedica Therapeutics Inc. (DMAC), including its current stock price, financial statistics, historical data, and analyst insights. It highlights DMAC as a clinical-stage biopharmaceutical company focused on ischemic diseases, with its lead candidate DM199 in Phase 2/3 trials. …

AbCellera Biologics Inc. • Robinhood Token (ABCL) Price Prediction for 2026 to 2031

This article provides price predictions for AbCellera Biologics Inc. • Robinhood Token (ABCL) from 2026 to 2045, based on Bybit AI's analysis of user-driven Consensus Ratings and historical patterns. It forecasts a positive trend for ABCL's price, with significant potential ROI over the years, …